Epstein Secrets

ht: how they are handling antitrust challenges from regulators with the authority to break them up." The Wall Street Journal (7/28, Tracy, McKinnon, Glazer, Subscription Publication, 7.57M) quotes Rep. David Cidlline (D-RI), who chairs the Antitrust Subcommittee, saying, "These platforms have been allo

by Pfizer and German biotech BioNTech SE to inoculate 50 million people at a price of $39 for a two-dose treatment course." Pfizer Chief Executive Albert Bourla is quoted as saying, "All the countries that are developed right now will not receive a lower price for the same volume commitment than the US." UN

em up." The Wall Street Journal <https://www.wsj.corn/articles/big-tech-to-appear-before-congress-on-wednesday-11595962801> (7/28, Tracy, McKinnon, Glazer, Subscription Publication, 7.57M) quotes Rep. David Cicilline (D-RI), who chairs the Antitrust Subcommittee, saying, "These platforms have been allo

by Pfizer and German biotech BioNTech SE to inoculate 50 million people at a price of $39 for a two-dose treatment course." Pfizer Chief Executive Albert Bourla is quoted as saying, "All the countries that are developed right now will not receive a lower price for the same volume commitment than the US." UN

t: how they are handling antitrust challenges from regulators with the authority to break them up." The Wall Street Journal (7/28, Tracy, McKinnon, Glazer, Subscription Publication, 7.57M) quotes Rep. David Cicilline (D-RI), who chairs the Antitrust Subcommittee, saying, "These platforms have been allo

by Pfizer and German biotech BioNTech SE to inoculate 50 million people at a price of $39 for a two-dose treatment course." Pfizer Chief Executive Albert Bourla is quoted as saying, "All the countries that are developed right now will not receive a lower price for the same volume commitment than the US." U

t: how they are handling antitrust challenges from regulators with the authority to break them up." The Wall Street Journal (7/28, Tracy, McKinnon, Glazer, Subscription Publication, 7.57M) quotes Rep. David Cicilline (D-RI), who chairs the Antitrust Subcommittee, saying, "These platforms have been allo

by Pfizer and German biotech BioNTech SE to inoculate 50 million people at a price of $39 for a two-dose treatment course." Pfizer Chief Executive Albert Bourla is quoted as saying, "All the countries that are developed right now will not receive a lower price for the same volume commitment than the US." U